After calling Rockville, Maryland, home for more than eight years, Big Pharma GSK is planning to move its vaccine and ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

The WHO has given a green light to widespread use of GlaxoSmithKline's malaria vaccine in Africa, in what could be a major turning point in the fight against the disease. The RTS,S/AS01 vaccine ...

GSK is doubling production of its AS01 adjuvant – used to boost the immune response to vaccines – for use in the malaria shot as it anticipates rising demand, and will work through its ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Both of the malaria vaccines prequalified by the World Health Organisation (WHO) and recommended for use in children are pre-erythrocytic. These are GSK’s Mosquirix (recommended since 2021 ...

GSK blames political and regulatory pressures for the decline in its vaccine’s business in 2024, as it expects sales to further shrink in 2025. Despite these challenges, GSK beat Q4 2024 ...

GlaxoSmithKline (GSK ... It’s not that the Gates Foundation is snubbing malaria vaccines — as one of Gavi’s biggest donors, Gates is helping to fund the R21 rollout. But rather than put ...

The ideal vaccine would be cheap, extremely safe, induce life-long immunity, be active against all strains of the parasite and result in nearly complete interruption of the malaria life cycle by ...

GSK adds that the strength of these will overcome short-term vaccine challenges from external pressures in the US and China. The Brentford, U.K.-based company remains confident that Arexvy ...

How do Sanofi CEO Paul Hudson and GSK CEO Emma Walmsley—who lead two of the top vaccine companies in the world—feel about the movement and how it could affect their businesses? Tuesday at the ...